Skip to content
POM-V Prescription Required Companion Animal

Cytopoint 40 mg/ml Solution for Injection

Active ingredient: Lokivetmab

Form

Injection

Species

Dogs

Manufacturer

Zoetis Belgium

VMD MA No.

EU/2/17/205/007-008,012

What it's used for

Treatment of pruritus associated with allergic dermatitis in dogs. Treatment of clinical manifestations of atopic dermatitis in dogs.

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Lokivetmab

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Cytopoint 40 mg/ml Solution for Injection — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Treatment of pruritus associated with allergic dermatitis in dogs.
Treatment of clinical manifestations of atopic dermatitis in dogs.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in dogs less than 3 kg bodyweight.
Dogs:
Rare
(1 to 10 animals / 10,000
animals treated):
Hypersensitivity reaction
(anaphylaxis, facial
oedema, urticaria)
Vomiting
, diarrhoea
Neurological signs (ataxia, convulsion, seizure)
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Injection site pain, injection site swelling
Clinical signs of immune mediated diseases (e.g.
immune-mediated haemolytic anaemia, immune-
mediated thrombocytopenia)

Revised: December 2023
AN: 03118/2022
In case of such reactions, appropriate treatment should be administered
immediately.
May occur in connection with hypersensitivity reactions. Treatment should be
administered as needed.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also the last section of the
package leaflet for contact details.
Lokivetmab may induce transient or persistent anti-drug antibodies. The induction of
such antibodies is uncommon and may have no effect (transient anti-drug antibodies)
or may result in a noticeable decrease in efficacy (persistent anti-drug antibodies) in
animals that responded to treatment previously.

Revised: December 2023
AN: 03118/2022

Special precautions for use in animals
Avoidance or elimination of the allergen is an important consideration in the
successful treatment of allergic dermatitis. When treating pruritus associated with
allergic dermatitis with lokivetmab, investigate and treat any underlying causes (e.g.
flea allergic dermatitis, contact dermatitis, food hypersensitivity); this product is not
intended to be used as a long-term maintenance therapy if the offending allergen(s)
can be successfully avoided or eliminated. Furthermore, in cases of allergic
dermatitis and atopic dermatitis, it is recommended to investigate and treat
complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g.
flea and mange).
It is recommended to monitor dogs for bacterial infections associated with atopic
dermatitis, especially during the first weeks of treatment.
If no or limited response is observed within one month after initial dosing, an
improvement in response may be observed after administration of a second dose
one month later. However, if the animal does not show a better response after the
second dose, the veterinary surgeon should consider alternative treatments.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case
of accidental self-injection.
Accidental self-injection may result in an immune response to lokivetmab. It is not
expected for this to cause any adverse effects, however, repeated self-administration
may increase the risk of hypersensitivity reactions.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.
No drug interactions were observed in field studies where lokivetmab was
administered concomitantly with veterinary medicinal products such as endo- and
ectoparasiticides, antimicrobials, anti-inflammatories and vaccines.
If a vaccine(s) is to be administered at the same time as treatment with lokivetmab,
the vaccine(s) should be administered at a different site to that of lokivetmab.
Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Store in the original package.
Protect from light.
Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.